Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative DR, Non-proliferative DR), by Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), by Region, and Segment Forecasts, 2022-2030


May 2022

 Pages: 120

 IMR 2482

The global diabetic retinopathy market size is expected to reach USD 13.8 billion by 2030 registering a CAGR of 6.4%. The incidence rate of diabetes has been increasing dramatically. According to the International Diabetes Federation, in 2021 there were about 537 million diabetic cases, which is projected to rise to 643 million by 2030 and 783 million by 2045. Diabetes is among the leading cause of blindness in people. Blindness is caused due to leaking or rupturing of retinal blood vessels, which may be permanent or temporary in nature depending on the disease stage. Studies suggest that in 2020 the number of diabetic retinopathy cases were about 103.12 million; the cases are expected to reach 160.5 million by 2045.

Rising patient awareness levels and increasing healthcare expenditure are also among the factors which are likely to propel market growth. Moreover, the increasing geriatric population in both developed and developing nations is expected to propel the market over the forecast period. According to the Population Reference Bureau report titled "Aging in the United States”, the number of people in the U.S. aged 65 years and over was projected to increase from around 46 million in 2016 to over 98 million by 2060. Early detection and treatment guidelines for diabetic retinopathy had significantly reduced due to the COVID-19 pandemic-related constraints. When compared to 2019, intravitreal injections for diabetic retinopathy had decreased significantly globally throughout the pandemic, ranging from around 30 to over 100 percent reduction. However, now that the lockdown restrictions have been removed, the market is expected to grow at a significant rate.

Diabetic Retinopathy Market Report Highlights
The non-proliferative diabetic retinopathy segment accounted for the largest revenue share, by type, in 2021. The presence of a large number of patients within the bracket of fewer than 10 years of diabetic history contributed to the large size of this segment

The anti-VEGF segment accounted for the largest revenue share, by management, in 2021. The high applicability of these drugs in the treatment and early diagnosis of mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth

In Asia Pacific, the market is expected to witness the highest CAGR over the forecast period. The large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market

Diabetic Retinopathy Market Segmentation
Grand View Research has segmented the global diabetic retinopathy market based on type, management, and region:

Diabetic Retinopathy Type Outlook (Revenue, USD Million, 2018 - 2030)

Proliferative diabetic retinopathy

Non-proliferative diabetic retinopathy

Diabetic Retinopathy Management Outlook (Revenue, USD Million, 2018 - 2030)


Intraocular steroid injection

Laser surgery


Diabetic Retinopathy Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America









Asia Pacific




South Korea


Latin America





Middle East and Africa

South Africa

Saudi Arabia


List of Key Players of Diabetic Retinopathy Market

Bayer AG

Allergan plc

Novartis AG

Oxurion NV

Sirnaomics Inc.


Alimera Sciences

Ampio Pharmaceuticals

BCN Peptides

Kowa Company, Ltd.

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!

  +91 810 895 3541